The Washington Post

FDA chief says pharmacy oversight at ‘critical point’

The Food and Drug Administration has reached a “critical point” in its struggle to oversee specialty pharmacies that have been associated with mounting illnesses and deaths, the head of the agency said Friday.

FDA Commissioner Margaret Hamburg’s comments came in response to a Washington Post investigation that found that shoddy practices and unsanitary conditions at three large-scale specialty pharmacies have been tied to deaths and illnesses over the past decade. Those safety lapses occurred long before national attention focused on New England Compounding Center (NECC), the Massachusetts company whose tainted steroid shots were at the center of last fall’s deadly meningitis outbreak.

Hamburg said the agency needs new, stronger and clearer legislation to oversee “firms engaged in large-scale distribution” of custom-mixed, or compounded, drugs, some of which were highlighted in the Post article. The current patchwork of federal and state laws is too weak to protect patients in all 50 states from high-risk compounding operations, she said in a statement.

“We’ve reached a critical point on this issue,” Hamburg said.

Rep. Edward J. Markey (D-Mass.), who released a report last fall showing uneven oversight by state authorities, said Friday that the FDA needs greater authority. He plans to reintroduce legislation that would allow the agency to regulate compounders that act more like drug manufacturers.

Here are basic steps a compounder could follow to make a drug.

“These compounding pharmacies have been operating under the radar for too long,” he said in a statement.

Pharmacies traditionally have mixed drugs to meet the specific needs of individual patients. But over the past two decades, compounding has become dominated by 15 companies that mass-produce medications and ship them to hospitals and clinics across state lines. The shipments are often based on anticipated needs, not on individual patient prescriptions.

Three of these large compounders, in addition to NECC, have experienced significant safety problems over the past decade that were tied to at least 39 illnesses, according to the Post’s analysis of hundreds of records and dozens of interviews. Two firms’ missteps were linked to at least six deaths. The problems included medications that were too potent or laced with bacteria.

The three companies are California-based Central Admixture Pharmacy Services, Illinois-based PharMEDium Services, and Texas-based ApotheCure. Officials of the companies have said that their firms produce safe, quality medications and adhere to the industry’s highest standards.

Lena H. Sun is a national reporter for The Washington Post, focusing on health.
Kimberly Kindy is a national investigative reporter at The Washington Post.

The Freddie Gray case

Please provide a valid email address.

You’re all set!

Campaign 2016 Email Updates

Please provide a valid email address.

You’re all set!

Get Zika news by email

Please provide a valid email address.

You’re all set!
Show Comments

Sign up for email updates from the "Confronting the Caliphate" series.

You have signed up for the "Confronting the Caliphate" series.

Thank you for signing up
You'll receive e-mail when new stories are published in this series.
Most Read



Success! Check your inbox for details.

See all newsletters

Close video player
Now Playing

To keep reading, please enter your email address.

You’ll also receive from The Washington Post:
  • A free 6-week digital subscription
  • Our daily newsletter in your inbox

Please enter a valid email address

I have read and agree to the Terms of Service and Privacy Policy.

Please indicate agreement.

Thank you.

Check your inbox. We’ve sent an email explaining how to set up an account and activate your free digital subscription.